The Face-Name Associative Memory Test as a Tool for Early Diagnosis of Alzheimer's Disease

Frontiers in Psychology
José Rubiño, Pilar Andrés

Abstract

One current challenge for neuropsychologists is to design assessment methods capable of detecting cognitive deficits in the early or preclinical phases of Alzheimer's disease (AD). The objective of this paper is to review the studies that have explored the use of the Face-Name Associative Memory Exam (FNAME) as a test for early diagnosis of AD. Studies looking at correlations between performance on the FNAME test and biomarkers in healthy people and studies comparing healthy controls and people with mild cognitive impairment are reviewed. These studies are based on the evidence that AD's pathological process begins years before the most visible clinical manifestations. We conclude that the FNAME test may be a valuable tool for early diagnosis but that some important questions remain to be resolved in future research.

References

Jan 1, 1990·Experimental Aging Research·V O LeirerG M Pariante
Oct 1, 1989·Journal of Clinical and Experimental Neuropsychology·D M MasurM K Aronson
Mar 11, 1999·Annals of Neurology·J L Price, J C Morris
Apr 6, 1999·Archives of Neurology·R C PetersenE Kokmen
Oct 16, 2003·Dementia and Geriatric Cognitive Disorders·Andrew D BlackwellJohn R Hodges
Mar 25, 2004·Lancet Neurology·Bruno Dubois, Martin L Albert
Oct 19, 2007·Cortex; a Journal Devoted to the Study of the Nervous System and Behavior·Katja Werheid, Linda Clare
Dec 17, 2009·Archives of Neurology·Ronald C PetersenClifford R Jack
Jul 2, 2010·Neurology·Carol F Lippa, Gael Chetelat
Jul 14, 2010·Brain : a Journal of Neurology·Mario A ParraSergio Della Sala
Feb 22, 2011·Neurobiology of Aging·Patrizia VanniniReisa A Sperling
Jun 22, 2011·Neuropsychologia·Dorene M RentzReisa A Sperling
Feb 1, 2012·Neuropsychologia·Sergio Della SalaSharon Abrahams
Jul 7, 2012·Journal of Clinical and Experimental Neuropsychology·Rebecca E AmariglioDorene M Rentz
Nov 10, 2012·Clinical Investigation·John C MorrisVirginia D Buckles
May 7, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Frank JessenUNKNOWN Subjective Cognitive Decline Initiative (SCD-I) Working Group
Aug 21, 2015·Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists·Montserrat AlegretMercè Boada
Oct 8, 2015·Journal of Alzheimer's Disease : JAD·Montserrat AlegretMercè Boada
Nov 9, 2016·Menopause : the Journal of the North American Menopause Society·Dorene M RentzJill M Goldstein
Jul 25, 2017·Lancet·Gill LivingstonNaaheed Mukadam

❮ Previous
Next ❯

Citations

Nov 24, 2019·The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences·Marie CaillaudSylvie Belleville
Jun 14, 2019·Frontiers in Psychology·Desirée Lopis, Laurence Conty
Nov 8, 2020·Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists·S Enriquez-GeppertP Andrés
Mar 23, 2021·Journal of the International Neuropsychological Society : JINS·Vanessa Alviarez-SchulzeUNKNOWN Barcelona Brain Health Initiative group
Sep 21, 2021·Journal of Clinical and Experimental Neuropsychology·Juan Francisco Flores VazquezPilar Andrés

❮ Previous
Next ❯

Methods Mentioned

BETA
nuclear magnetic resonance

Software Mentioned

FNAME

Related Concepts

Related Feeds

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.